Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market Wednesday that its third quarter revenues increased more than six-fold year over year on increased test volume.

The San Diego-based maker of cancer biomarker assays reported total revenues of about $1 million for the three months ended Sept. 30, up from $164,856 for the third quarter of 2015. It said that it accessioned 1,179 billable samples during the quarter, a 122 percent increase over the 531 samples for the third quarter of 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Sponsored by

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.